Savage Joshua, Manka Madeleine, Rindels Tiffany, Alom Manaf, Sharma Kiran L, Trost Landon
Male Fertility and Peyronie's Clinic, Orem, UT, USA.
Mayo Clinic, Rochester, MN, USA.
Transl Androl Urol. 2020 Feb;9(1):73-81. doi: 10.21037/tau.2019.09.41.
Vasovasostomy (VV) is a well-described surgical technique with few notable modifications since microsurgical adaptation in the 1970s. Although contemporary reversal success rates are 70-90%, these most often are based on a lenient definition of >0 sperm (patency) and include only VV procedures. With stricter definitions, success rates drop >30%. To improve outcomes, a novel surgical technique (reinforcing vasal suture, ReVas) was developed, and outcomes were compared prior to and following implementation.
A prospective registry of sequential patients undergoing vasectomy reversal was queried from Jan 2014 to June 2019. The ReVas technique was implemented in Jan 2018, wherein the abdominal and testicular vasa are secured side-to-side to alleviate strain on the anastomosis. Primary outcomes were changes in sperm concentration: >0/mL, >100,000/mL, >1 million/mL, >5 million/mL, >15 million/mL, and most recent. Secondary outcome was pregnancy rate. Demographic, clinical, and select operative variables were statistically compared between ReVas (+) and (-) cohorts.
A total of 200 men underwent reversal, of whom 169 represented first-time attempts (61 receiving the new technique) and comprise the current cohort. ReVas (+) and (-) cohorts were similar in demographic, clinical, and operative factors with the exception of operative time [longer in ReVas (+) group]. Median duration since vasectomy was 9 years, and 68.6% of men received a bilateral VV. Follow-up was significantly longer in the ReVas (-) arm (37 10 months). All primary outcomes were significantly higher in the ReVas (+) cohort, with odds ratios ranging from 5.8 to 11.1 (P<0.01 to 0.0001). Pregnancy rates within the first 2 years post reversal were also 8.1× higher in the ReVas (+) group (P=0.02). A subset of men with bilateral VV exhibited a 95% likelihood of achieving >15 million/mL in ReVas (+) men compared to 54% in ReVas (-). Multivariable analysis confirmed ReVas as an independent predictor of success.
Implementation of the ReVas technique resulted in significantly higher sperm concentrations, which were particularly pronounced when stricter success criteria were used. Patients were also 8.1× more likely to achieve a pregnancy within the first 2 years, confirming clinical relevance. External validation is warranted.
输精管吻合术(VV)是一种自20世纪70年代显微外科应用以来已有详细描述的手术技术,几乎没有显著的改进。尽管当代的复通成功率为70%-90%,但这些成功率大多基于对精子数>0(通畅)的宽松定义,且仅包括输精管吻合术。采用更严格的定义时,成功率会下降超过30%。为了改善手术效果,开发了一种新的手术技术(强化输精管缝合术,ReVas),并对该技术实施前后的效果进行了比较。
查询了2014年1月至2019年6月接受输精管复通术的连续患者的前瞻性登记资料。ReVas技术于2018年1月开始应用,该技术将腹部输精管和睾丸输精管并排固定,以减轻吻合处的张力。主要结局指标为精子浓度的变化:>0/mL、>100,000/mL、>100万/mL、>500万/mL、>1500万/mL以及最近一次的精子浓度。次要结局指标为妊娠率。对ReVas(+)组和(-)组的人口统计学、临床和部分手术变量进行了统计学比较。
共有200名男性接受了输精管复通术,其中169名是首次尝试(61名接受了新技术),构成了当前的研究队列。ReVas(+)组和(-)组在人口统计学、临床和手术因素方面相似,但手术时间除外[ReVas(+)组更长]。输精管结扎术后的中位时间为9年,68.6%的男性接受了双侧输精管吻合术。ReVas(-)组的随访时间明显更长(37±10个月)。ReVas(+)组的所有主要结局指标均显著更高,优势比范围为5.8至11.1(P<0.01至0.0001)。复通术后前2年内的妊娠率在ReVas(+)组中也高出8.1倍(P=·02)。与ReVas(-)组的54%相比,双侧输精管吻合术的部分男性在ReVas(+)组中达到>1500万/mL的可能性为95%。多变量分析证实ReVas是成功的独立预测因素。
ReVas技术的应用导致精子浓度显著更高,在采用更严格的成功标准时尤为明显。患者在术后前2年内实现妊娠的可能性也高出8.1倍,证实了该技术的临床相关性。需要进行外部验证。